MARKET

TARA

TARA

Protara Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

41.19
+3.38
+8.94%
After Hours: 41.19 0 0.00% 16:51 05/22 EDT
OPEN
39.49
PREV CLOSE
37.81
HIGH
41.98
LOW
38.39
VOLUME
25.60K
TURNOVER
--
52 WEEK HIGH
42.49
52 WEEK LOW
8.80
MARKET CAP
240.68M
P/E (TTM)
-2.1853
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TARA stock price target is 45.00 with a high estimate of 45.00 and a low estimate of 45.00.

EPS

TARA News

More
Stocks That Hit 52-Week Highs On Friday
On Friday, 46 stocks hit new 52-week highs.
Benzinga · 3d ago
Stocks That Hit 52-Week Highs On Wednesday
During Wednesday's morning session, 85 stocks hit new 52-week highs.
Benzinga · 5d ago
Protara Therapeutics Announces First Quarter 2020 Financial Results and Business Overview
GlobeNewswire · 05/13 13:00
ArTara Therapeutics Q1 EPS $(1.810) Down From $(0.580) YoY
ArTara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(1.810) per share. This is a 212.07 percent decrease over losses of $(0.580) per share from the same period last year.
Benzinga · 05/13 12:08
ArTara Therapeutics Announces Corporate Name Change to Protara Therapeutics
ArTara Therapeutics, Inc. (TARA), a clinical-stage company identifying and advancing transformative therapies for people with rare and specialty diseases, today announced that it has changed its name to Protara Therapeutics, Inc., effective immediately. As pa
GlobeNewswire · 05/11 12:38
ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 05/05 21:05
Taro Pharma Names Daphne Huang CFO, Chief Accounting Officer
Benzinga · 04/06 16:28
ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 04/02 12:00

Industry

Biotechnology & Medical Research
+1.01%
Pharmaceuticals & Medical Research
+0.05%

Hot Stocks

Symbol
Price
%Change

About TARA

Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases. Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. Its product pipeline includes TARA 002 and IV choline chloride for injection. TARA 002 is its lead program focused on the treatment of Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is an enzyme replacement therapy for patients with choline deficiency who exhibit symptoms of liver impairment. IV Choline Chloride is being developed for the treatment of Intestinal Failure Associated Liver Disease (IFALD).
More

Webull offers kinds of Protara Therapeutics Inc stock information, including NASDAQ:TARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARA stock news, and many more online research tools to help you make informed decisions.